Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Licaminlimab by Oculis for Keratoconjunctivitis Sicca (Dry Eye): Likelihood of Approval
Licaminlimab is under clinical development by Oculis and currently in Phase II for Keratoconjunctivitis Sicca (Dry Eye). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Oculis's Licaminlimab?
Licaminlimab is a monoclonal antibody commercialized by Oculis, with a leading Phase II program in Anterior Uveitis. According to Globaldata,...
Licaminlimab by Oculis for Anterior Uveitis: Likelihood of Approval
Licaminlimab is under clinical development by Oculis and currently in Phase II for Anterior Uveitis. According to GlobalData, Phase II...